Kirkland advised Lilly Asia Ventures (LAV), a leading biomedical venture capital firm, in the one and final closing of its sixth USD life sciences funds, LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P. at their hard cap. The funds were heavily oversubscribed with a broad mix of prestigious global institutional investors, including sovereigns, pensions, endowments, foundations, family offices and fund of funds. Kirkland also represented LAV in raising its predecessor funds LAV Biosciences Funds III, IV and V.
The team was led by investment funds partners Carol Liu and Jennifer Feng, associates Ling Zhu and Yeshu Yang, and foreign legal consultant Nicole Yang. The team also included investment funds partner Josh Westerholm and Reed Schuster and associates Lucy Lam, Jasmine Wee and Danielle Sartain, tax partners Dan Meehan and Aalok Virmani and associates Andrew Chan and Michael Alcan, government & internal investigations partners Michael Casey and Nick Niles, employee benefits partner Liz Dyer, banking regulatory of counsel Julie Kunetka and international trade and national security partner Mario Mancuso and associate Luci Hague.